A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- Drug: JNJ-80948543
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 220
- Registration Number
- NCT05424822
- Locations
- 🇫🇷
Institut de Cancerologie Strasbourg Europe ICANS, Strasbourg, France
🇺🇸City of Hope, Duarte, California, United States
🇨🇳Tianjin cancer hospital, Tianjin, China
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
- Conditions
- Lymphoma, Non-HodgkinLymphoma, B-Cell
- Interventions
- Biological: JNJ-90014496
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 230
- Registration Number
- NCT05421663
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇺🇸City of Hope, Duarte, California, United States
A Study of JNJ-63733657 in Healthy Chinese Participants
- Conditions
- Healthy
- Interventions
- Drug: JNJ-63733657
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT05407818
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05401214
- Locations
- 🇲🇽
DUMMY, Dummy, Mexico
A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants
- Conditions
- Healthy
- Interventions
- Drug: Aticaprant Supratherapeutic DoseDrug: Aticaprant Therapeutic DoseDrug: PlaceboDrug: Moxifloxacin
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT05387759
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Advanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 418
- Registration Number
- NCT05388669
- Locations
- 🇪🇸
Hosp. Univ. Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain
🇪🇸Hosp. Univ. Lucus Augusti, Lugo, Spain
🇪🇸Hosp. Gral. Univ. Gregorio Maranon, Madrid, Spain
A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: DRV/COBI FDCDrug: COBIDrug: DRV
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT05378906
- Locations
- 🇧🇪
SGS Belgium NV, Edegem, Belgium
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
- Conditions
- Advanced or Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 225
- Registration Number
- NCT05379595
- Locations
- 🇺🇸
O Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸University of California, Los Angeles UCLA, Los Angeles, California, United States
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
- Conditions
- Myositis
- Interventions
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT05379634
- Locations
- 🇺🇸
University of Pennsylvania - Perelman School of Medicine, Philadelphia, Pennsylvania, United States
🇺🇸Wexner Medical Center at the Ohio State University, Columbus, Ohio, United States
🇺🇸The Brigham and Women's Hospital, Inc., Boston, Massachusetts, United States
A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: JNJ-77242113
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 227
- Registration Number
- NCT05364554
- Locations
- 🇯🇵
Shizuoka General Hospital, Shizuoka, Japan
🇬🇧Guys and St Thomas NHS Foundation Trust, London, United Kingdom
🇺🇸Pacific Skin Institute, Sacramento, California, United States